c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells

Neo Wenhao, Junfeng Lim, Raelene Joy Grumont, Steven Demetrious Gerondakis, Su I-Hsin

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)

Abstract

Check for full text(opens in a new window) Library catalogue(opens in a new window) View at Publisher Export Download More... Journal of Biological Chemistry Volume 289, Issue 46, 14 November 2014, Pages 31693-31707 C-rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells (Article) Neo, W.H.a, Lim, J.F.a, Grumont, R.b, Gerondakis, S.b, Su, I.-H.a a School of Biological Sciences, College of Science, Nanyang Technological University, 60 Nanyang Dr., Singapore, Singapore b Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia View references (60) Abstract The polycomb group protein Ezh2 is a histone methyltransferase that modifies chromatin structure to alter gene expression during embryonic development, lymphocyte activation, and tumorigenesis. The mechanism by which expression is regulated is not well defined. In the current study, we report that c-Rel is a critical activator of Ezh2 transcription in lymphoid cells. In activated primary murine B and T cells, plus human leukemia and multiple myeloma cell lines, recruitment of c-Rel to the first intron of the Ezh2 locus promoted Ezh2 mRNA expression. This up-regulation was abolished in activated c-Rel-deficient lymphocytes and by c-Rel knockdown in Jurkat T cells. Treatment of malignant cells with the c-Rel inhibitor pentoxifylline not only reduced c-Rel nuclear translocation and Ezh2 expression, but also enhanced their sensitivity to the Ezh2-specific drug, GSK126 through increased growth inhibition and cell death. In summary, our demonstration that c-Rel regulates Ezh2 expression in lymphocytes and malignant lymphoid cells reveals a novel transcriptional network in transformed lymphoid cells expressing high levels of Ezh2 that provides a molecular justification for combinatorial drug therapy.
Original languageEnglish
Pages (from-to)31693 - 31707
Number of pages15
JournalThe Journal of Biological Chemistry
Volume289
Issue number46
DOIs
Publication statusPublished - 2014

Cite this